Advertisement
Research Article

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

  • Roger H. Brookes,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Philip C. Hill,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Patrick K. Owiafe,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Hannah B. Ibanga,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • David J. Jeffries,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Simon A. Donkor,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Helen A. Fletcher,

    Affiliation: Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

    X
  • Abdulrahman S. Hammond,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Christian Lienhardt,

    Affiliation: Institut de Recherche pour le Développement, Paris, France

    X
  • Richard A. Adegbola,

    Affiliation: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia

    X
  • Helen McShane mail,

    helen.mcshane@ndm.ox.ac.uk

    Affiliation: Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

    X
  • Adrian V. S. Hill

    Affiliations: Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

    X
  • Published: August 13, 2008
  • DOI: 10.1371/journal.pone.0002921

About the Authors

Roger H. Brookes, Philip C. Hill, Patrick K. Owiafe, Hannah B. Ibanga, David J. Jeffries, Simon A. Donkor, Abdulrahman S. Hammond, Richard A. Adegbola
Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia
Helen A. Fletcher, Helen McShane, Adrian V. S. Hill
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
Christian Lienhardt
Institut de Recherche pour le Développement, Paris, France
Adrian V. S. Hill
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

Corresponding Author

Email: helen.mcshane@ndm.ox.ac.uk

Competing Interests

RHB has a patent relating to ex vivo ELISPOT licensed through Oxford University. AH and HM are named inventors on a composition of matter patent for MVA85A filed by the University of Oxford. There are no other conflicts of interest

Author Contributions

Conceived and designed the experiments: RHB PCH SAD HF CL RAA HM AVH. Performed the experiments: RHB PO HBI AH. Analyzed the data: RHB PCH PO HBI DJJ SAD HF AH HM AVH. Contributed reagents/materials/analysis tools: PCH HF HM AVH. Wrote the paper: RHB PCH PO HBI DJJ AH CL RAA HM AVH. Recruited and examined the volunteers: PCH.